BSE · 524828
BDH Industries Ltd.
Revenue & net profit by period
Bars = revenue (₹ Cr) · line = net profit (₹ Cr). Straight from disclosed results.
Latest period: revenue ₹98 Cr with net profit ₹11 Cr — a 11.01% net margin, versus 13.57% the period before.
Shareholding
As of 2026-09-30
- Promoter49.7%
- Public50.03%
- FII0.28%
4,525 shareholders on record
Promoter holding trend
Each disclosed period, oldest to newest
52-week position
Where the current price sits in its yearly band
The band spans 1.79× from low to high.
Risk flags
Derived from disclosed data
No flags raised by the data.
Peer comparison
Pharmaceuticals - Indian - Formulations · ranked #22 of 51 by market cap · medians across 43 industry peers
| Company | Mkt cap | P/E | P/B | ROE | Margin |
|---|---|---|---|---|---|
| Torrent Pharmaceuticals Limited | ₹1,73,440 Cr | 77.73 | 20.62 | 11.42% | 12.27% |
| Gland Pharma Limited | ₹46,800 Cr | 40.84 | 4.52 | 9.92% | 16.78% |
| Ajanta Pharma Limited | ₹42,101 Cr | 37.1 | 9.3 | 23.33% | 19.65% |
| Rubicon Research Limited | ₹24,606 Cr | 85.38 | 19.09 | 19.14% | 14.89% |
| Shilpa Medicare Ltd. | ₹17,530 Cr | 61.64 | 6.77 | 9.39% | 17.67% |
| Caplin Point Laboratories Ltd. | ₹17,483 Cr | 26.28 | 5.19 | 17.88% | 29.09% |
| Eris Lifesciences Limited | ₹15,184 Cr | 23.12 | 3.89 | 15.87% | 20.04% |
| Marksans Pharma Limited | ₹13,296 Cr | 25.74 | 4.4 | 13.82% | 16.29% |
| Bliss GVS Pharma Ltd. | ₹6,500 Cr | 47.22 | 5.45 | 10.82% | 13.55% |
| Senores Pharmaceuticals Limited | ₹5,711 Cr | 45.19 | 6.12 | 12.36% | 18.59% |
| BDH Industries Ltd.(this company) | ₹242 Cr | 20.66 | 3.2 | 14.04% | 11.74% |
AI analysis
AI-generated · google/gemini-2.5-flashBDH Industries Ltd. is listed with a market capitalization of Rs 320 Cr. The company reported an EPS of 18.77 and a book value of 131.42. The return on equity (ROE) is 14.04% and return on capital employed (ROCE) is 19.30%. The debt-to-equity ratio stands at 0.08. The company's profit margin is 11.28%.
Positives
- +The debt-to-equity ratio is low at 0.08.
- +Return on Capital Employed (ROCE) is 19.3015%.
- +Return on Equity (ROE) is 14.04%.
- +The promoter pledge is 0% of shares.
Negatives
- −Annual revenue decreased by 21.81% from Rs 87.4117 Cr in Mar 2024 to Rs 68.3471 Cr in Mar 2025.
- −Annual net profit decreased by 6.02% from Rs 9.8678 Cr in Mar 2024 to Rs 9.2733 Cr in Mar 2025.
- −Promoter shareholding of 49.6958% is below 50% as of June 30, 2026.
- −Quarterly net profit for Mar 2026 was Rs 2.88 Cr, a decrease from Rs 3.49 Cr in Dec 2025.
Financial Performance
BDH Industries Ltd. reported annual revenue of Rs 68.3471 Cr in Mar 2025, a decrease from Rs 87.4117 Cr in Mar 2024. Net profit for Mar 2025 was Rs 9.2733 Cr, down from Rs 9.8678 Cr in Mar 2024. Quarterly revenue for Mar 2026 was Rs 29.03 Cr, with a net profit of Rs 2.88 Cr. In the preceding quarter, Dec 2025, revenue was Rs 29.34 Cr and net profit was Rs 3.49 Cr.
Profitability & Returns
The company's profit margin is 11.28%. BDH Industries Ltd. delivered a Return on Equity (ROE) of 14.04% and a Return on Capital Employed (ROCE) of 19.3015%. Annual EPS in Mar 2025 was 16.11, a decline from 17.14 in Mar 2024. The trailing twelve months EPS is 18.77.
Balance Sheet
BDH Industries Ltd. has a low debt-to-equity ratio of 0.08. The book value per share is 131.42. The company has not pledged any promoter shares.
Ownership & Pledges
As of June 30, 2026, promoter shareholding was 49.6958%, while public shareholding stood at 50.0259%. Institutions (FIIs) held 0.2783%. There were no promoter shares pledged as of the latest disclosure.
Regulatory & Surveillance
There is no information available regarding any surveillance measures for BDH Industries Ltd.
Data as of — price: 2026-10-26 · financials: Mar 26 · shareholding: Sep 26. Figures are restated only when the company files again, so a period shown here is the most recent one on record — not necessarily the current quarter.
How this is produced: every figure above is computed from exchange filings and financial data mirrored by IPO Plus — no figure is generated or estimated. This is a factual summary for information and education only. It is not investment advice, not a recommendation to buy, sell or hold any security, and contains no price targets. Verify against the company's filings and the exchanges before any decision.